What Is 1 of the Best Pharmaceutical Stocks to Buy Now?

Key Points

Anti-obesity drugs are being considered for a range of addictive behaviors. Pfizer just acquired a next-generation, clinical-stage maker of obesity treatments. 10 stocks we like better than Pfizer ›

What's the hottest trend in the pharmaceutical industry right now?

You could make a strong argument that it's the expansion of so-called GLP-1 medications. These miracle drugs effectively promote weight loss (in addition to treating diabetes), but there's growing evidence that they can also tame cravings for alcohol and narcotics, and even mitigate behaviors like sex addiction and gambling.

Right now, the major manufacturers of GLP-1 drugs are Novo Nordisk(NYSE: NVO), which makes Wegovy, and Eli Lilly(NYSE: LLY), which manufactures Zepbound. These are already blockbuster drugs, and they're bound to get even bigger. Demand for and sales of the weight loss drugs are only expected to accelerate, and the size of the anti-obesity drug market is forecast to hit $100 billion within five years.Image source: Getty Images.

A third major player

But a third major pharma player is emerging in the GLP-1 space.

That would be Pfizer(NYSE: PFE), which is now getting into the weight loss market. In September, it announced that it would acquire Metsera, a next-generation, clinical-stage biopharmaceutical company that's developing several obesity treatments. The price of the acquisition is $4.9 billion.

One of Metsera's drug candidates, MET-233i, can be taken less frequently than the Novo Nordisk and Lilly drugs, and has proven highly effective -- it helped patients in one study to lose 8.4% of their body weight in 36 days.

These weight loss drugs are big, and rapidly getting bigger. An investment in Pfizer today could pay off in a major way as this trend continues.

Should you buy stock in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

Story Continues

See the 10 stocks »

*Stock Advisor returns as of October 27, 2025

Matthew Benjamin has positions in Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

What Is 1 of the Best Pharmaceutical Stocks to Buy Now? was originally published by The Motley Fool

View Comments